Heartstream wrapping up clinical study of user-friendly, biphasic external defibrillator.
This article was originally published in The Gray Sheet
HEARTSTREAM CLINICAL STUDY FOR USER-FRIENDLY BIPHASIC EXTERNAL DEFIBRILLATOR is expected to be completed early this year, the company says. The clinical trial, involving 200 patients at 12 sites, is currently under way and has "very clearly" demonstrated the efficacy of the automatic external defibrillator (AED), Heartstream President and CEO Alan Levy said Jan. 10 at the Hambrecht & Quist life sciences conference in San Francisco. Heartstream plans to file a 510(k) for the defibrillator before the end of this year.
You may also be interested in...
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Nutritional Brands rolls out NB Pure as brand, including logo, packaging design and website, for all its supplements after 25 years. “When you looked at our label for one brand and looked at the label for another brand, there was no symmetry between the two,” says CEO Danna Pratt.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.